- Home
- RPRX vs UHS Comparison
RPRX vs UHS Comparison
Compare RPRX & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- UHS
- Stock Information
- Founded
- RPRX 1996
- UHS 1978
- Country
- RPRX United States
- UHS United States
- Employees
- RPRX N/A
- UHS N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- UHS Hospital/Nursing Management
- Sector
- RPRX Health Care
- UHS Health Care
- Exchange
- RPRX Nasdaq
- UHS Nasdaq
- Market Cap
- RPRX 13.9B
- UHS 12.1B
- IPO Year
- RPRX 2020
- UHS N/A
- Fundamental
- Price
- RPRX $33.58
- UHS $172.68
- Analyst Decision
- RPRX Strong Buy
- UHS Buy
- Analyst Count
- RPRX 3
- UHS 17
- Target Price
- RPRX $47.33
- UHS $222.31
- AVG Volume (30 Days)
- RPRX 5.5M
- UHS 655.0K
- Earning Date
- RPRX 05-08-2025
- UHS 07-23-2025
- Dividend Yield
- RPRX 2.62%
- UHS 0.46%
- EPS Growth
- RPRX 37.60
- UHS 51.30
- EPS
- RPRX 2.45
- UHS 17.80
- Revenue
- RPRX $2,263,845,000.00
- UHS $16,084,073,000.00
- Revenue This Year
- RPRX $29.35
- UHS $9.34
- Revenue Next Year
- RPRX $7.58
- UHS $5.62
- P/E Ratio
- RPRX $13.70
- UHS $9.70
- Revenue Growth
- RPRX 1.13
- UHS 9.73
- 52 Week Low
- RPRX $24.05
- UHS $153.99
- 52 Week High
- RPRX $34.32
- UHS $243.25
- Technical
- Relative Strength Index (RSI)
- RPRX 56.69
- UHS 34.89
- Support Level
- RPRX $33.37
- UHS $188.14
- Resistance Level
- RPRX $33.97
- UHS $191.00
- Average True Range (ATR)
- RPRX 0.53
- UHS 5.12
- MACD
- RPRX 0.05
- UHS -2.15
- Stochastic Oscillator
- RPRX 76.06
- UHS 14.82
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.